The Evolving Treatment Landscape for Metastatic Differentiated Thyroid Cancer

od Grande, Carolyn, Brose, Marcia S.
Izdano u J Adv Pract Oncol (2014)

The Challenges of Clinical Research in Rare Cancers: Bevacizumab Use in Low-Grade Serous Ovarian and Primary Peritoneal Cancers

od Grande, Carolyn, Visovsky, Constance, Brose, Marcia S.
Izdano u J Adv Pract Oncol (2017)

Ectopic Cushing’s Syndrome and Severe Hypocalcemia Due to Medullary Thyroid Cancer Responsive to Selpercatinib

od Turin, Christie Gloria, Brose, Marcia S, White, Caitlin A
Izdano u J Endocr Soc (2021)

Lack of BRAF mutations in hyalinizing trabecular neoplasm

od Baloch, Zubair W, Puttaswamy, Kanchan, Brose, Marcia, LiVolsi, Virginia A
Izdano 2006

RAP1GAP inhibits cytoskeletal remodeling and motility in thyroid cancer cells

od Dong, Xiaoyun, Tang, Waixing, Stopenski, Stephen, Brose, Marcia S, Korch, Christopher, Meinkoth, Judy L
Izdano 2012

A Phase I Study of Cabozantinib (XL184) in Patients with Differentiated Thyroid Cancer

od Cabanillas, Maria E., Brose, Marcia S., Holland, Jaymes, Ferguson, Kimberly C., Sherman, Steven I.
Izdano 2014

Distribution of dendritic cell subtypes in primary oral squamous cell carcinoma is inconsistent with a functional response

od O’Donnell, Rebekah K., Mick, Rosemarie, Feldman, Michael, Hino, Satoshi, Wang, Yan, Brose, Marcia S., Muschel, Ruth J.
Izdano 2007

Downregulation of Rap1GAP in Human Tumor Cells Alters Cell/Matrix and Cell/Cell Adhesion

od Tsygankova, Oxana M., Ma, Changqing, Tang, Waixing, Korch, Christopher, Feldman, Michael D., Lv, Yu, Brose, Marcia S., Meinkoth, Judy L.
Izdano 2010

Downregulation of Rap1GAP Contributes to Ras Transformation

od Tsygankova, Oxana M., Prendergast, Gregory V., Puttaswamy, Kanchan, Wang, Yan, Feldman, Michael D., Wang, Hongbin, Brose, Marcia S., Meinkoth, Judy L.
Izdano 2007

Timing of multikinase inhibitor initiation in differentiated thyroid cancer

od Brose, Marcia S, Smit, Johannes, Lin, Chia-Chi, Pitoia, Fabian, Fellous, Marc, DeSanctis, Yoriko, Schlumberger, Martin, Tori, Masayuki, Sugitani, Iwao
Izdano u Endocr Relat Cancer (2017)

Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas

od Dougherty, Margaret J., Santi, Mariarita, Brose, Marcia S., Ma, Changqing, Resnick, Adam C., Sievert, Angela J., Storm, Phillip B., Biegel, Jaclyn A.
Izdano 2010

Body Composition in Patients with Radioactive Iodine-Refractory, Advanced Differentiated Thyroid Cancer Treated with Sorafenib or Placebo: A Retrospective Analysis of the Phase III...

od Huillard, Olivier, Jouinot, Anne, Tlemsani, Camille, Brose, Marcia S., Arrondeau, Jennifer, Meinhardt, Gerold, Fellous, Marc, De Sanctis, Yoriko, Schlumberger, Martin, Goldwasser, Francois
Izdano u Thyroid (2019)

THE RET/PTC-3 ONCOGENE ACTIVATES CLASSICAL NF-κB BY STABILIZING NIK

od Neely, Robert J., Brose, Marcia S., Gray, Carolyn M., McCorkell, Kelly A., Leibowitz, Jason M, Ma, Changqing, Rothstein, Jay L., May, Michael J.
Izdano 2010

Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, p...

od Brose, Marcia S, Cabanillas, Maria E, Cohen, Ezra E W, Wirth, Lori J, Riehl, Todd, Yue, Huibin, Sherman, Prof Steven I, Sherman, Eric J
Izdano u Lancet Oncol (2016)

Application of a BRAF Pyrosequencing Assay for Mutation Detection and Copy Number Analysis in Malignant Melanoma

od Spittle, Cynthia, Ward, M. Renee, Nathanson, Katherine L., Gimotty, Phyllis A., Rappaport, Eric, Brose, Marcia S., Medina, Angelica, Letrero, Richard, Herlyn, Meenhard, Edwards, Robin H.
Izdano 2007

Rationale and design of decision: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced o...

od Brose, Marcia S, Nutting, Christopher M, Sherman, Steven I, Shong, Young Kee, Smit, Johannes WA, Reike, Gerhard, Chung, John, Kalmus, Joachim, Kappeler, Christian, Schlumberger, Martin
Izdano 2011

Physician and Stakeholder Perceptions of Conflict of Interest Policies in Oncology

od Lockhart, A. Craig, Brose, Marcia S., Kim, Edward S., Johnson, David H., Peppercorn, Jeffrey M., Michels, Dina L., Storm, Courtney D., Schuchter, Lynn M., Rathmell, W. Kimryn
Izdano u J Clin Oncol (2013)

MON-521 An Open-Label, Single-Arm, Multicenter, Phase 2 Trial of Lenvatinib (LEN) for the Treatment of Anaplastic Thyroid Cancer (ATC)

od Wirth, Lori J, Brose, Marcia S, Sherman, Eric J, Misir, Soamnauth, Xie, Sharon, Almonte, Ana, Ye, Weifei, Licitra, Lisa, Schlumberger, Martin, Sherman, Steven I, Cabanillas, Maria
Izdano u J Endocr Soc (2020)

Phase II Trial of Sorafenib in Advanced Thyroid Cancer

od Gupta-Abramson, Vandana, Troxel, Andrea B., Nellore, Anoma, Puttaswamy, Kanchan, Redlinger, Maryann, Ransone, Kathy, Mandel, Susan J., Flaherty, Keith T., Loevner, Laurie A., O'Dwyer, Peter J., Brose, Marcia S.
Izdano 2008

Exposure–Response Modeling and Simulation of Progression‐Free Survival and Adverse Events of Sorafenib Treatment in Patients With Advanced Thyroid Cancer

od Grevel, Joachim, Jentsch, Garrit, Austin, Rupert, Prins, Nicolaas H., Lettieri, John, Mitchell, David, Huang, Funan, Brose, Marcia S., Schlumberger, Martin, Meinhardt, Gerold, Peña, Carol E. A., Ploeger, Bart A.
Izdano u Clin Transl Sci (2019)